The FDA has granted priority review to a new drug application (NDA) seeking the approval of sonrotoclax (BGB-11417; BeOne ...
From Trial Diversity to Telehealth: Advancing Equity and Access in Rural and Underserved Cancer Care
There was also a shared emphasis on expanding and integrating clinical trials through broadening trial eligibility criteria ...
Antonio Urbina, MD, the medical director for the Mount Sinai Institute for Advanced Medicine 7th Avenue clinic in New York ...
Final 5-year data from the phase 2 2102-HEM-101 trial (NCT02719574) show that olutasidenib (Rezlidhia; Rigel Pharmaceuticals, ...
Panelists discuss how next-generation metabolic and hepatic agents are broadening treatment options and reshaping the MASH ...
Ryan Haumschild, PharmD, MS, MBA, introduces the faculty and sets the agenda to explore disease background, novel therapies, ...
Real-world data on usage of the tyrosine kinase inhibitor nintedanib (Ofev; Boehringer Ingelheim) suggest there is ...
The study shows a significant drop in CRS and ICANS risk 15 days after liso-cel infusion, supporting reduced monitoring ...
Among more than 7.8 million CRC screenings, the share of patients aged 45 to 49 years jumped from 2.9% before the guideline changes to 17.8% afterward. The average monthly screenings for this younger ...
Total social media time does not significantly affect adolescents' weight concerns or dieting frequency, according to the study's findings. New research reveals that total social media use does not ...
Panelists discuss how integrating clinical efficacy with cost-effectiveness ensures sustainable adoption of MASH therapies. Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights ...
Resmetirom effectively resolves MASH and improves fibrosis, independent of GLP-1 or SGLT2 inhibitor use, in patients with T2DM. Achieving ≥5% weight loss enhances resmetirom's effects on MASH ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback